SAB Biotherapeutics, Inc. (SABS)
| Market Cap | 255.67M+21.4% |
| Revenue (ttm) | n/a-100.0% |
| Net Income | n/a+65.5% |
| EPS | n/a+78.5% |
| Shares Out | 90.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 216,532 |
| Open | 2.83 |
| Previous Close | 2.88 |
| Day's Range | 2.80 - 2.91 |
| 52-Week Range | 2.10 - 5.15 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 11.33(+303.20%) |
| Earnings Date | n/a |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About SABS
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
$SABS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in SABS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SABS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SABS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SABS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SABS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SABS
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $8.38M |
| IWMiShares Russell 2000 ETF | $3.84M |
| VXFVanguard Extended Market ETF | $2.40M |
| VTWOVanguard Russell 2000 ETF | $925.70K |
| IWCiShares Micro-Cap ETF | $491.96K |
| SBIOALPS Medical Breakthroughs ETF | $330.34K |
Estimated from each fund’s disclosed top holdings × AUM
SABS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SABS’s recent data — informational, not investment advice